Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Curr Probl Cancer ; 47(4): 100993, 2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-37418998

RESUMEN

Nearly 15% of individuals with localized prostate cancer are identified as high risk for recurrence and progression of the disease, which is why the correct staging is vital for the definition of correct treatment-also developing novel therapeutic strategies to find a balance between getting better outcomes without sacrificing the quality of life (QoL). In this narrative review, we introduced the current standards of staging and primary treatment of high-risk localized prostate cancer (PCa), based on international guidelines and arguments in the debate, under the light of the most recent literature. It brings essential tools such as PSMA PET/CT and different nomograms (Briganti. MSKCC, Gandaglia) for accurate staging and selecting wisely the definitive therapy. Even though there is a broad discussion over the best local treatment in curative-intent treatment, it looks more important to define which patient profile would adapt correctly to every different treatment, highlighting the benefits and superior outcomes with multimodal treatment.


Asunto(s)
Tomografía Computarizada por Tomografía de Emisión de Positrones , Neoplasias de la Próstata , Masculino , Humanos , Calidad de Vida , Neoplasias de la Próstata/diagnóstico , Neoplasias de la Próstata/terapia , Neoplasias de la Próstata/patología , Nomogramas , Estadificación de Neoplasias
2.
urol. colomb. (Bogotá. En línea) ; 30(3): 210-216, 15/09/2021. tab
Artículo en Inglés | LILACS, COLNAL | ID: biblio-1369434

RESUMEN

Introduction It is known that cancer care is best approached by a multidisciplinary team (MDT). This became specifically true in the Covid-19 pandemic in which choices for urological cancer treatment are influenced by many factors. In some cases, delayed treatment may have consequences regarding the patient's oncological outcomes. The aim of the present article is to report our experience throughout the Covid-19 pandemic treating patients with urological neoplasms at a high-volume center. Methods We used a convenience sampling method. Cases were evaluated and discussed on an individual basis at the MDT meetings, and, after a consensus regarding delaying or scheduling treatment, patients were scheduled according to the risk of postponing the procedures. The Medically Necessary, Time-Sensitive (MeNTS) scoring system was measured in each patient; all patients answered the Centers for Disease Control and Prevention (CDC) Covid-19 self-screening questionnaire prior to surgery. The Covid-19-free survival rate was estimated. Results A total of 194 patients were assessed by themultidisciplinary team and finally treated, with median follow-up of 4 (interquartile range [IQR]: 2.75 to 6) months. Only two patients had Covid-19 confirmed by real-time polymerase chain reaction (RT-PCR). In total, 54 patients underwent oncological surgery, 129 were treated with radiotherapy, and 11 were treated with intravenous chemotherapy. Themedian age was 66 years (IQR: 59 to 94 years), and the median MeNTS score in the surgically-treated cohort was 35 points (IQR: 31 to 47 points). Conclusions The evaluation and treatment of urological cancer should be conducted by an MDT; this is of utmost importance, especially during the Covid-19 pandemic. The data collected in our institution showed that most patients could be safely treated by taking all necessary precautions and discussing each case individually in the MDT meetings and performing a close follow-up.


Introduccion La atención del cáncer se aborda mejor con un equipo multidisciplinario (EMD), aspecto que se tornó más importante en la pandemia por Covid-19, en que las opciones para tratar el cáncer urológico están influenciadas por muchos factores. En algunos casos, el tratamiento retrasado puede tener consecuencias en los resultados oncológicos del paciente. El objetivo de este estudio es describir nuestra experiencia en un centro de referencia y de alto volumen para el tratamiento de neoplasias urológicas durante la pandemia por Covid-19. Métodos Realizamos un muestreo por conveniencia. Posteriormente, los casos fueron evaluados y discutidos de forma individual en las reuniones del EMD. Posterior a la obtención de un consenso sobre el tratamiento del paciente, los pacientes fueron programados según el riesgo individual de posponer el manejo. Se midió la puntuación de cada paciente en el sistema Medically Necessary Time-Sensitive (MeNTS, "Médicamente necesario, sensibles al tiempo"). Todos los pacientes respondieron el cuestionario de autoevaluación del Centers for Disease Control and Prevention (CDC) COVID-19 antes de la cirugía. Se estimó la tasa de supervivencia libre de Covid-19. Resultados Un total de 194 pacientes fueron evaluados por el EMD y finalmente tratados, con una mediana de seguimiento de 4 (rango intercuartil [RIC]: 2,75 a 6) meses. Solo dos tenían Covid-19 confirmado por reacción en cadena de la polimerasa en tiempo real (RCP-TR). Un total de 54 pacientes fueron sometidos a cirugía oncológica, 129 fueron tratados con radioterapia, y 11 fueron tratados con quimioterapia intravenosa. La mediana de edad fue de 66 años (RIC: 59 a 94 años), la puntuación mediana en el MeNTS de la cohorte tratada quirúrgicamente fue de 35 puntos (RIC: 31 a 47 puntos). Conclusiones La evaluación y el tratamiento del cáncer urológico debe ser realizado por un EMD durante la pandemia de Covid-19. Los datos recopilados en nuestra institución mostraron que la mayoría de los pacientes podrían ser tratados de manera segura, discutiendo cada caso individualmente y haciendo un seguimiento cercano.


Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Terapéutica , Neoplasias Urológicas , COVID-19 , Cuidados Posteriores , Centers for Disease Control and Prevention, U.S. , Quimioterapia , Reacción en Cadena en Tiempo Real de la Polimerasa , Tiempo de Tratamiento
3.
BMC Urol ; 20(1): 105, 2020 Jul 20.
Artículo en Inglés | MEDLINE | ID: mdl-32689980

RESUMEN

BACKGROUND: Stauffer Syndrome (SS) is a paraneoplastic disorder associated with renal cell carcinoma (RCC). First described by Herbert Maurice Stauffer in 1961, it is characterized by hepatic dysfunction in the absence of metastasis, and elevated alkaline phosphatase, aminotransferases and prolonged prothrombin time. Initial reports did not include jaundice as an inclusion criterion. We aim to report the rare SS jaundice variant in a patient with a small renal mass and review the literature to determine if the size of the renal mass could influence the development of the SS. CASE PRESENTATION: The aim of this article is to present the case of a 53-year-old male with Stauffer syndrome jaundice variant secondary to a 2.5 cm renal mass, treated with laparoscopic radical nephrectomy with complete resolution of the syndrome. CONCLUSIONS: This syndrome is yet to be fully understood, and as far as the evidence shows, size does not matter. This entity should always be in mind when encountered with a patient with liver dysfunction and jaundice with a suspicion or confirmed diagnosis of a renal mass. To date, and to our knowledge, there have been eleven reported cases of paraneoplastic cholestatic jaundice syndrome including the current case. Six cases presented in patients with small renal mases (< 4 cm), curiously there were not a laterality tendency.


Asunto(s)
Carcinoma de Células Renales/complicaciones , Carcinoma de Células Renales/patología , Neoplasias Renales/complicaciones , Neoplasias Renales/patología , Hepatopatías/etiología , Síndromes Paraneoplásicos/etiología , Humanos , Masculino , Persona de Mediana Edad , Carga Tumoral
4.
Rev. colomb. cancerol ; 20(2): 92-95, abr.-jun. 2016. ilus
Artículo en Español | LILACS | ID: lil-797410

RESUMEN

La ruptura espontánea de la vejiga se considera una urgencia urológica que requiere un alto índice de sospecha para realizar el diagnóstico y su tratamiento puede llegar a tener gran complejidad. Se reporta un caso de una paciente de 54 años, con antecedente de cáncer de cuello uterino tratado con radioterapia en 1993 y un sarcoma pleomorfo en la región lumbar-sacra manejada con cirugía, quimioterapia y radioterapia en el 2007. Consultó al servicio de urgencias por un cuadro de dolor progresivo en el hipogastrio, emesis e incontinencia de orina mixta. En la tomografía abdominal y pélvica hubo evidencia de extravasación del medio de contraste en la pared posterior de vejiga. Se practicó una laparotomía exploratoria y sutura vesical. La paciente presentó una adecuada evolución y en el seguimiento la tomografía pélvica fue normal.


Spontaneous rupture of the bladder is considered a urological emergency requiring a high index of suspicion for its diagnosis, and treatment can have a high degree of complexity. A case is presented of a 54 year-old patient with a history of cervical cancer treated with radiotherapy in 1993, and pleomorphic sarcoma in the lumbar and sacral region that received management with surgery, chemotherapy and radiotherapy in 2007. She consulted in the emergency room with symptoms of progressive lower abdomen pain, emesis, and mixed urinary incontinence. The abdominal and pelvic tomography showed no evidence of extravasation of the contrast medium in the posterior wall of the bladder. An exploratory laparotomy and bladder suture was performed. The patient showed adequate progress and the follow-up pelvic scan was normal.


Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Radioterapia , Rotura Espontánea , Vejiga Urinaria , Sarcoma , Terapéutica , Neoplasias del Cuello Uterino , Quimioterapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...